One in three smokers remained smoke-free, compared to seven percent on placebo
For generations, the grip of nicotine has resisted most attempts at a clean break, leaving millions of smokers cycling through failed treatments or none at all. Now, a plant-derived compound called cytisnicline has completed its final human trials with results that place it among the more promising cessation tools in recent memory — roughly one in three daily smokers who took it remained smoke-free, against a backdrop of fifteen years without a new approved option. The drug works quietly, occupying the brain's nicotine receptors without the cigarette, easing the body toward freedom rather than forcing it. Whether regulators will open the door to its wider use remains the next chapter in a story that touches the lives of hundreds of millions.
- Smoking kills more people than any other preventable cause worldwide, and the existing pharmacological toolkit has gone without a new addition for fifteen years — a silence that cytisnicline may finally break.
- In a trial of 810 daily smokers, the drug produced a 32.6% abstinence rate over twelve weeks, dwarfing the 7% seen in placebo groups and signaling a clinically meaningful leap forward.
- Unlike some existing treatments that trade one burden for another, cytisnicline showed a remarkably clean side-effect profile — fewer than 3% of participants stopped taking it due to adverse reactions.
- Achieve Life Sciences has yet to file with the FDA or any international regulator, meaning the drug remains a published promise rather than an available prescription as of mid-2023.
- The company targets an FDA submission in early 2024, which, if successful, would bring the first new cessation medication to international markets in a decade and a half.
A plant-derived drug called cytisnicline has cleared its final round of human testing with results that could meaningfully expand how doctors treat nicotine addiction. In a trial of 810 daily smokers in the United States, roughly one in three participants who took the drug for twelve weeks remained smoke-free in the weeks that followed — compared to just seven percent among those given a placebo. If approved, it would be the first new smoking cessation medication to reach international markets in fifteen years.
The drug works by binding to the brain's nicotine receptors, mimicking the chemical signal a cigarette would deliver without the smoker actually lighting up. The effect suppresses cravings and softens withdrawal, following a mechanism similar to varenicline but potentially offering relief to those for whom existing treatments have failed or proven intolerable. The twelve-week course outperformed the six-week regimen, with 21.1% of participants still abstinent three months after finishing treatment, against 4.8% in the control group.
Perhaps as notable as the efficacy data is what the drug did not do. Serious adverse events were absent entirely. Abnormal dreams and insomnia affected fewer than one in ten participants, and headache and nausea rates were comparable to placebo. Only 2.9% of people discontinued because of side effects — a figure that stands in contrast to the tolerability concerns that have historically limited uptake of other cessation drugs.
Harvard Medical School's Nancy Rigotti, a lead researcher on the study, underscored the importance of expanding the available options, noting that no single treatment works for everyone. The findings have been published in JAMA, lending them institutional weight. Still, Achieve Life Sciences has not yet submitted cytisnicline to any regulatory body. The company plans to seek FDA approval in the first half of 2024, with international reviews to follow. Until that process concludes, the drug remains a well-documented possibility — but for the hundreds of millions of smokers searching for a way out, the trial results suggest that possibility is drawing closer.
A plant-derived medication called cytisnicline has emerged from its final round of human testing with results that could reshape how doctors treat nicotine addiction. In a trial of 810 daily smokers across the United States, roughly one in three people who took the drug for twelve weeks remained smoke-free weeks later—a result that stands in sharp contrast to the seven percent abstinence rate among those given a placebo. If regulatory agencies approve it, cytisnicline would become the first new smoking cessation drug to reach international markets in fifteen years.
The medication works by occupying the same neural real estate that nicotina normally claims. When a smoker inhales, nicotine floods the brain's receptors and creates the chemical craving that keeps people tethered to cigarettes. Cytisnicline binds to those same receptors, tricking the brain into thinking it has received its dose without the smoker actually lighting up. The result is a suppressed urge to smoke and a gentler withdrawal experience than quitting cold turkey. The drug's mechanism mirrors that of varenicline, which has been available in the United States and Brazil for years, but cytisnicline appears to offer a new option for the millions of smokers for whom existing treatments either don't work or produce intolerable side effects.
The trial, which tested both six-week and twelve-week treatment courses, found the longer regimen most effective. Between weeks nine and twenty, 32.6 percent of participants in the twelve-week group had not returned to smoking. Three months after finishing the treatment, 21.1 percent remained abstinent—compared to just 4.8 percent in the control group. The drug proved remarkably well-tolerated. Abnormal dreams and insomnia affected fewer than ten percent of participants in each group. Headaches and nausea occurred at rates similar to placebo. Only 2.9 percent of people stopped taking the medication because of side effects, and no serious adverse events were recorded.
Nancy Rigotti, a Harvard Medical School professor and one of the study's lead researchers, emphasized the significance of having another tool in the arsenal. Current medications do not work for everyone and often carry unwanted consequences. Cytisnicline, if approved, could reach people whom existing drugs have failed. The World Health Organization recognizes smoking as the leading preventable cause of death globally, making any advance in treatment a matter of public health consequence.
The path forward remains uncertain in terms of timing. Achieve Life Sciences, the company developing cytisnicline, has not yet submitted the drug to any regulatory body. The company plans to seek approval from the U.S. Food and Drug Administration in the first half of 2024. Brazil's National Health Surveillance Agency and other international regulators have not yet reviewed the medication. The clinical evidence has been published in JAMA, the Journal of the American Medical Association, lending it credibility within the medical establishment. Until approval comes, cytisnicline remains a promise rather than a prescription—but for the hundreds of millions of smokers worldwide searching for a way out, the trial results suggest that promise may soon become reality.
Citações Notáveis
Current medications do not help all smokers quit and produce unwanted side effects in others. If approved, cytisnicline could offer a new option for treating smoking, the leading preventable cause of death worldwide.— Nancy Rigotti, Harvard Medical School researcher
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is the first new drug in fifteen years? Aren't there already options?
There are—varenicline and nicotine replacement therapy work for some people. But they don't work for everyone, and they come with side effects that make others quit the medication before they quit smoking. A new mechanism, a new chemical pathway, gives doctors something else to offer when the first option fails.
How does cytisnicline actually feel different from existing drugs, from a patient's perspective?
The trial data doesn't tell us much about subjective experience—just that fewer people reported nausea, headaches, or insomnia compared to other treatments. But mechanically, it's doing the same thing varenicline does: sitting in the brain's nicotine receptors so the smoker doesn't feel the craving. The difference is probably subtle, but for someone whose body rejected the old drug, subtle can mean the difference between success and failure.
The quit rate is one in three. That sounds good, but two in three people still failed. Why frame this as a breakthrough?
Because the placebo group had a seven percent quit rate. That's the baseline—people who want to quit but get no chemical help. Cytisnicline more than quadrupled that. And three months later, when most people relapse, the drug group still had four times the abstinence rate. It's not perfect, but it's real improvement at scale.
When will people actually be able to take this?
Not for a while. The company hasn't even filed for FDA approval yet—they're planning to do that in early 2024. Approval itself could take months or years. So we're probably looking at 2025 or later before a smoker could walk into a pharmacy and fill a prescription, assuming the FDA says yes.
What about people smoking vapes instead of cigarettes? Does this work for them?
That's an open question. The trial was mostly conventional cigarette smokers. The researchers acknowledge they'll need more studies to understand how cytisnicline affects people addicted to electronic nicotine. It's a gap in the evidence right now.